SCC008 Sigma-AldrichReNcell® VM Human Neural Progenitor Cell LIne
ReNcell® VM is an immortalized human neural progenitor cell line with the ability to readily differentiate into neurons & glial cells.
More>> ReNcell® VM is an immortalized human neural progenitor cell line with the ability to readily differentiate into neurons & glial cells. Less<<Recommended Products
Overview
Replacement Information |
---|
Key Spec Table
Key Applications |
---|
Cult |
Description | |
---|---|
Catalogue Number | SCC008 |
Brand Family | Chemicon® |
Trade Name |
|
Description | ReNcell® VM Human Neural Progenitor Cell LIne |
Overview | ReNcell® VM is an immortalized human neural progenitor cell line with the ability to readily differentiate into neurons and glial cells. ReNcell® VM was derived from the ventral mesencephalon region of human fetal brain. Immortalized by retroviral transduction with the v-myc oncogene, this cell line grows rapidly as a monolayer on laminin with a doubling time of 20-30 hours. Karyotype analyses indicate that the ReNcell® VM retains a normal diploid karyotype in culture even after prolonged passage (>45 passages). ReNcell® VM was developed by the ReNeuron Group plc, a biotech company that specializes in using human somatic stem cells for therapeutics. In experiments performed by the ReNeuron Group plc, ReNcell® VM can be differentiated in vitro to a high level of human dopaminergic neurons. Neurons differentiated from ReNcell® VM have furthermore been shown to be electophysiologically active. ReNcell® VM may be used for a variety of research applications such as studies of neurotoxicity, neurogenesis, electrophysiology, neurotransmitter and receptor functions. ReNcell® VM cells have been obtained in a legal and ethical manner, compliant with current local informed consent procedures. ReNcell Now Used in a 3D Cell Model of Alzheimer's Disease! Tanzi, R and Kim, DY et. al. A three-dimensional human neural cell culture model of Alzheimer's disease. Nature. 2014 Nov 13;515(7526):274-8. (Published in Nature) |
Materials Required but Not Delivered | 1. ReNcell® NSC Maintenance Medium (Millipore Cat. No. SCM005) 2. ReNcell® NSC Freezing Medium (Millipore Cat. No. SCM007) 3. Basic fibroblast growth factor (bFGF; FGF-2; Specific Activity > 2 X 106 Units/mg. Millipore Cat. No. GF003) 4. Epidermal growth factor (EGF; Specific Activity > 1 x 107 Units/mg; MilliporeCat. No. GF001) 5. Laminin (Millipore Cat. No. CC095) 6. DMEM/F12 w/o HEPES, w/ L-Glutamine (Millipore Cat. No. DF-042-B) 7. Accutase (Millipore Cat. No. SCR005) 8. Tissue culture-ware 9. Phosphate-Buffered Saline (1X PBS) (Millipore Cat. No. BSS-1005-B) 10. Fixative (e.g. 4% Paraformaldehyde in 1X PBS) 11. Blocking Solution (5% normal donkey serum, 0.3% Triton X-100 in 1X PBS) 12. Primary and secondary antibodies 13. 4'-6-Diamidino-2-phenylindole (DAPI) / PBS solution 14. Anti-fading mounting solution (DABCO/PVA) 15. Hemacytometer 16. Microscope |
References |
---|
Product Information | |
---|---|
Components |
|
HS Code | 3002 15 90 |
Quality Level | MQ100 |
Applications | |
---|---|
Application | ReNcell® VM is an immortalized human neural progenitor cell line with the ability to readily differentiate into neurons & glial cells. |
Key Applications |
|
Biological Information | |
---|---|
Source | Human ventral mesencephalon brain tissue |
Stem Cell Type |
|
Cell Line Type |
|
Physicochemical Information |
---|
Dimensions |
---|
Materials Information |
---|
Toxicological Information |
---|
Safety Information according to GHS |
---|
Safety Information |
---|
Product Usage Statements | |
---|---|
Quality Assurance | Each lot of ReNcell® VM cells has been validated for high level of expression of Nestin and Sox 2 and for their self-renewal and multi-lineage differentiation capacities. Cells also display normal karyotype as assessed by chromosome spread and tested negative for mycoplasma. Maternal blood has been screened for HIV, HTLV, Hepatitis B and C. |
Usage Statement |
|
Packaging Information | |
---|---|
Material Size | 1 ea |
Transport Information |
---|
Supplemental Information |
---|
Specifications |
---|
Global Trade Item Number | |
---|---|
Catalogue Number | GTIN |
SCC008 | 04053252662713 |
Documentation
ReNcell® VM Human Neural Progenitor Cell LIne SDS
Title |
---|
References
Reference overview | Application | Pub Med ID |
---|---|---|
A dynamic view of the proteomic landscape during differentiation of ReNcell VM cells, an immortalized human neural progenitor line. Song, Y; Subramanian, K; Berberich, MJ; Rodriguez, S; Latorre, IJ; Luria, CM; Everley, R; Albers, MW; Mitchison, TJ; Sorger, PK Sci Data 6 190016 2019 Show Abstract | 30778261 | |
A three-dimensional human neural cell culture model of Alzheimer's disease. Choi, SH; Kim, YH; Hebisch, M; Sliwinski, C; Lee, S; D'Avanzo, C; Chen, H; Hooli, B; Asselin, C; Muffat, J; Klee, JB; Zhang, C; Wainger, BJ; Peitz, M; Kovacs, DM; Woolf, CJ; Wagner, SL; Tanzi, RE; Kim, DY Nature 2014 Show Abstract | 25307057 | |
Dynamic mass redistribution assay decodes differentiation of a neural progenitor stem cell. Pai, S; Verrier, F; Sun, H; Hu, H; Ferrie, AM; Eshraghi, A; Fang, Y Journal of biomolecular screening 17 1180-91 2012 Show Abstract | 22885730 | |
Interplay between REST and nucleolin transcription factors: a key mechanism in the overexpression of genes upon increased phosphorylation. Tediose, Teeo, et al. Nucleic acids research, (2010) 2010 Show Abstract | 20100803 | |
Transcriptional signature and memory retention of human-induced pluripotent stem cells. Marchetto, Maria C N, et al. PLoS ONE, 4: e7076 (2009) 2009 Show Abstract | 19763270 | |
Differential development of neuronal physiological responsiveness in two human neural stem cell lines. Donato, R; Miljan, EA; Hines, SJ; Aouabdi, S; Pollock, K; Patel, S; Edwards, FA; Sinden, JD BMC neuroscience 8 36 2007 Show Abstract | Immunocytochemistry | 17531091 |
Technical Info
Data Sheet
Title |
---|
ReNcell VM Human Neural Progenitor Cell Line |
Newsletters / Publications
Title |
---|
Cellutions Newsletter: 2007, Volume 1 |
Cellutions Newsletter: 2008, Volume 1 |
Cellutions Newsletter: 2008, Volume 3 |